Abbott Labs: Q3 results above estimates
(CercleFinance.com) - Abbott Laboratories has reported Q3 2018 adjusted net income from continuing operations that is up 16% at 1.
34 billion dollars, or 75 cents per share, EPS that is one cent above the consensus.
At 7.7 billion dollars, the healthcare group's revenue grew by 12.1% as reported, and was up 7.8% in organic terms, mainly driven by medical equipment (+9.8% in organic terms).
At the time of this publication, Abbott Laboratories said that it is tightening its target range for adjusted EPS from continuing operations to between 2.87 dollars and 2.89 dollars, saying that it is "well-positioned to achieve the upper end of our initial full-year guidance."
Copyright (c) 2018 CercleFinance.com. All rights reserved.
34 billion dollars, or 75 cents per share, EPS that is one cent above the consensus.
At 7.7 billion dollars, the healthcare group's revenue grew by 12.1% as reported, and was up 7.8% in organic terms, mainly driven by medical equipment (+9.8% in organic terms).
At the time of this publication, Abbott Laboratories said that it is tightening its target range for adjusted EPS from continuing operations to between 2.87 dollars and 2.89 dollars, saying that it is "well-positioned to achieve the upper end of our initial full-year guidance."
Copyright (c) 2018 CercleFinance.com. All rights reserved.